CoChat
Sign Up
Cited by 232Blood Pressure and Hypertension StudiesDialysis and Renal Disease ManagementChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial

Open access
Agarwal, Rajiv, Sinha, Arjun D., Pappas, Maria K., Abraham, Terri N., Tegegne, Getachew G.·2014·Nephrology Dialysis Transplantation
DOI 10.1093/ndt/gft515PMC PMC3938300
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: The purpose of this study was to determine among maintenance hemodialysis patients with echocardiographic left ventricular hypertrophy and hypertension whether in comparison with a β-blocker-based antihypertensive therapy, an angiotensin converting enzyme-inhibitor-based antihypertensive therapy causes a greater regression of left ventricular hypertrophy. METHODS: Subjects were randomly assigned to either open-label lisinopril (n = 100) or atenolol (n = 100) each administered three times per week after dialysis. Monthly monitored home blood pressure (BP) was controlled to <140/90 mmHg with medications, dry weight adjustment and sodium restriction. The primary outcome was the change in left ventricular mass index (LVMI) from baseline to 12 months. RESULTS: At baseline, 44-h ambulatory BP was similar in the atenolol (151.5/87.1 mmHg) and lisinopril groups, and improved similarly over time in both groups. However, monthly measured home BP was consistently higher in the lisinopril group despite the need for both a greater number of antihypertensive agents and a greater reduction in dry weight. An independent data safety monitoring board recommended termination because of cardiovascular safety. Serious cardiovascular events in the atenolol group occurred in 16 subjects, who had 20 events, and in the lisinopril group in 28 subjects, who had 43 events {incidence rate ratio (IRR) 2.36 [95% confidence interval (95% CI) 1.36-4.23, P = 0.001]}. Combined serious adverse events of myocardial infarction, stroke and hospitalization for heart failure or cardiovascular death in the atenolol group occurred in 10 subjects, who had 11 events and in the lisinopril group in 17 subjects, who had 23 events (IRR 2.29, P = 0.021). Hospitalizations for heart failure were worse in the lisinopril group (IRR 3.13, P = 0.021). All-cause hospitalizations were higher in the lisinopril group [IRR 1.61 (95% CI 1.18-2.19, P = 0.002)]. LVMI improved with time; no difference between drugs was noted. CONCLUSIONS: Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number: NCT00582114).

Overview

Integrity signals

Registry

Crossref · 10.1093/ndt/gft515

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 22 references

Cited by

Sorted by citations

Items 201–232 of 232

Related

See all

Metadata

Authors
Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., & Tegegne, G. G.
Affiliations
Richard L. Roudebush VA Medical Center (US)
Corresponding author
Agarwal, Rajiv
ORCID
Venue
Nephrology Dialysis Transplantation
Publisher
Oxford University Press (OUP)
Published
2014-01-06
Volume
29
Issue
3
Pages
672-681
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
DOI
10.1093/ndt/gft515
PMC
PMC3938300
OpenAlex
W2162199393
Cited by
232
References
22
Citations by year
2026: 13 · 2025: 12 · 2024: 14 · 2023: 19 · 2022: 15 · 2021: 18 · 2020: 21 · 2019: 16 · 2018: 19 · 2017: 19 · 2016: 24 · 2015: 24 · 2014: 17
FWCI
19.24
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • Nephrology Dialysis Transplantation (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, other-oa)
  • Purdue University Indianapolis (Indiana University) (submittedVersion, other-oa)
  • Publisher
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (2R01-DK063020-10)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
hypertension, hemodialysis, lisinopril, atenolol, left ventricular hypertrophy, left ventricular mass index, antihypertensive therapy, ACE inhibitors, beta-blockers, cardiovascular events, heart failure hospitalization, dry weight adjustment, sodium restriction, end-stage renal disease, ambulatory blood pressure monitoring, cardiovascular safety, trial termination
MeSH terms
Adult, Aged, Antihypertensive Agents, Atenolol, Double-Blind Method, Female, Renal Dialysis, Humans, Hypertension, Kidney Failure, Chronic, Male, Middle Aged, Myocardial Infarction, Treatment Failure, Hypertrophy, Left Ventricular, Lisinopril, Early Termination of Clinical Trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review